Hans-Henrik Parving.

However, no improvement in the primary composite outcome was observed, suggesting that factors such as hyperkalemia, renal dysfunction, and hypotension are likely involved in offsetting any beneficial effect of the treatment.17 When used individually, both ACE inhibitors and ARBs have been shown to decrease the incidence of major cardiovascular and renal events in patients with a variety of cardiovascular disorders and those with nephropathy.6,7,18-20 However, with the exception of two trials involving individuals with chronic center failure,21,22 the mix of these agents has not incrementally improved cardiovascular or renal outcomes as compared with monotherapy, and combination therapy has been associated with an increased incidence of hyperkalemia, hypotension, and renal dysfunction.11,24 Aliskiren is an efficient antihypertensive agent25 and, when put into either an ACE inhibitor or an ARB, has improved surrogate markers for clinical outcomes in some, however, not all, studies.Senate on legislation that permanently fixes what’s wrong with our health care system. Related StoriesACA launches nationwide effort to eliminate anti-competitive provision of Medicare lawNHS hourglass framework holds back development of support workforceMedicare patients in rural settings have lower rates of post-discharge follow-up careThe House plan makes prescription medications more affordable by enabling Medicare to negotiate prescription medication prices and closing the Part D coverage gap known as the doughnut hole.